A Chinese drugmaker with close military ties is seeking fast-track approval for a drug that it says can cure Ebola, as China joins the race to help treat a deadly outbreak of a disease that has spread from Africa to the United States and Europe.
Medical
Abbott, Mylan silent on why changing tax-inversion terms
Drugmakers Abbott Laboratories (ABT.N) and Mylan Inc (MYL.O) on Wednesday declined to explain in detail why they changed the terms of a $5.3 billion deal in which Mylan will buy part of Abbott's overseas generics business and reincorporate for tax purposes in the Netherlands.
Advent, Avista near deal for UCB's Kremers Urban
A consortium of buyout firms Advent International Corp and Avista Capital Partners is in advanced talks to acquire UCB SA's (UCB.BR) U.S. generic drugs unit Kremers Urban Pharmaceuticals Inc, according to people familiar with the matter.
Shire CFO to leave drugmaker as AbbVie drops bid
British drugmaker Shire (SHP.L) will lose its interim chief financial officer early next year to water supplier Severn Trent (SVT.L), the latest blow for Shire, whose proposed $55-billion acquisition by U.S. rival AbbVie (ABBV.N) was aborted last week.
Investors eye third quarter medical use from hospitals, insurers
Hospitals and insurers are expected to give their clearest view yet on whether people are having more surgeries and other medical procedures during the next few weeks when they report earnings, according to investors who are closely watching U.S. medical services use.
Latest News
California-based Mapp Biopharmaceutical Inc is making progress in efforts to boost production of the experimental Ebola treatment ZMapp, as the deadly virus continues to spread through West Africa and beyond, the company said Friday.
EU antitrust regulators will open an extensive probe into Zimmer's (ZMH.N) $13.4 billion bid for Biomet, concerned that the creation of the world's second-largest orthopedic products group may hurt competition, three people familiar with the matter said on Thursday.
Two tiny companies are preparing to challenge some of the world's largest drug makers in the battle for dominance in the $3 billion global market for influenza vaccines, armed with little more than tiny tobacco plants.
Johnson & Johnson (JNJ.N) agreed to pay $1.75 billion in cash to buy privately held Alios BioPharma Inc, which is developing a drug for a common respiratory viral infection in children for which there is no approved treatment.
Japanese drugmaker Daiichi Sankyo Co Ltd (4568.T) has agreed to acquire U.S. biopharmaceutical company Ambit Biosciences Corp (AMBI.O) in a deal valued up to $410 million as it looks to build its presence in oncology, the companies said.
Blackstone Group L.P. (BX.N) has agreed to buy a stake in China's Xinrong Best Medical Instrument Co, the U.S. private equity firm said in a statement on Tuesday. Blackstone did not give the size of the stake or other financial details.
GlaxoSmithKline may have closed one chapter in a saga of corruption allegations by accepting a $489 million fine in China, but the drugmaker has its work cut out to win back skeptical investors.
Israeli-company EndyMed Ltd has reached an agreement with the Chinese OHMK Medical Technology, which will acquire 47.93 million EndyMed shares (28.94 percent share capital and voting rights), for $7 million.
A smartphone app that rids you of acne. Another that monitors your heart rate 24-7. One that detects skin cancer by looking at your birthmarks. If they sound too good to be true, they may be.
